^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Repatha (evolocumab)

    i
    Other names: AMG 145, AMG-145, AMG145
    Company:
    Amgen, Astellas, Dr. Reddy’s
    Drug class:
    PCSK9 inhibitor
    Related drugs:
    3d
    Impact of PCSK9 inhibitor on T lymphocyte subsets and cytokines in patients with acute ischemic stroke: an exploratory analysis of a randomized clinical trial. (PubMed, Front Neurol)
    In this study, a total of 100 patients with AIS were included for the current analysis (n = 50 for combination therapy of evolocumab and atorvastatin, PI group, n = 50 for atorvastatin monotherapy, AT group). http://www.chictr.org.cn; Identifier: ChicTR2200059445. Date of registration: 29 April 2022.
    Clinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Repatha (evolocumab) • atorvastatin
    18d
    EVACS: Evolocumab in Acute Coronary Syndrome (clinicaltrials.gov)
    P2, N=60, Completed, Johns Hopkins University | Trial completion date: Oct 2024 --> Mar 2025
    Trial completion date
    |
    Repatha (evolocumab)
    1m
    EMPOWER: The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk (clinicaltrials.gov)
    P4, N=50, Recruiting, Brigham and Women's Hospital | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Repatha (evolocumab)
    1m
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Nov 2026 --> Nov 2025
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    2ms
    A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma. (PubMed, Sci Rep)
    Increased tumoral evolocumab/PCSK9i may enhance tumoral MHC-I/effector CD8+ infiltration. Future work will explore combining evolocumab with BBB/BTB opening therapies like low-intensity focused ultrasound.
    Journal
    |
    CD8 (cluster of differentiation 8) • FASLG (Fas ligand) • HLA-E (Major Histocompatibility Complex, Class I, E) • GZMA (Granzyme A)
    |
    Repatha (evolocumab)
    3ms
    PCSK9-PROVE: PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy (clinicaltrials.gov)
    P2/3, N=478, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New P2/3 trial
    |
    Repatha (evolocumab) • Praluent (alirocumab)
    4ms
    NEWTON-CABG: Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (clinicaltrials.gov)
    P4, N=782, Completed, Unity Health Toronto | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Jan 2025
    Trial completion • Trial completion date
    |
    Repatha (evolocumab)
    4ms
    Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China (clinicaltrials.gov)
    P=N/A, N=4000, Not yet recruiting, Beijing Tiantan Hospital
    New trial
    |
    Repatha (evolocumab)
    4ms
    VESALIUS-CV: Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (clinicaltrials.gov)
    P3, N=12301, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion
    |
    APOB (Apolipoprotein B)
    |
    Repatha (evolocumab)
    4ms
    Effects of evolocumab on periprocedural myocardial injury in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention (ChiCTR2500104994)
    P=N/A, N=100, Completed, The second hospital of Hebei Medical University; The second hospital of Hebei Medical University
    New trial
    |
    Repatha (evolocumab)
    4ms
    VINCENT: Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels (clinicaltrials.gov)
    P2, N=69, Recruiting, NewAmsterdam Pharma | N=30 --> 69
    Enrollment change
    |
    Repatha (evolocumab)
    5ms
    The use of monoclonal antibodies for the treatment of atherosclerosis: current status and prospects. (PubMed, Cell Mol Biol (Noisy-le-grand))
    Notably, anti-PCSK9 antibodies like alirocumab and evolocumab have demonstrated significant reductions in LDL-C levels and cardiovascular events in large-scale clinical trials. Overall, monoclonal antibody therapy represents a significant advancement in the management of atherosclerosis, with ongoing research aimed at optimizing efficacy, safety, and accessibility. Future directions include the development of novel mAbs and combination therapies to further improve cardiovascular outcomes in patients with atherosclerotic disease.
    Review • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta)
    |
    Repatha (evolocumab) • Praluent (alirocumab)